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Abstract
Introduction: The clinical scenario of a new or worsening pleural effusion following the initiation of
antituberculous therapy has been classically referred to as a ‘paradoxical’ pleural response, presumably explained by
an immunological rebound phenomenon. Emerging evidence suggests that there also may be a role for a lupus-
related reaction in the pathophysiology of this disorder.
Case presentation: An 84-year-old Asian man treated with isoniazid, along with rifampin, pyrazinamide and
ethambutol for suspected extrapulmonary tuberculosis, presented with a recurrent pleural effusion, his third
episode since the initiation of this therapy. The first effusion occurred one month after the start of treatment,
without any prior evidence of pulmonary tuberculosis involvement. Follow-up testing, including thoracoscopic
pleural biopsies, never confirmed tuberculosis infection. Further evaluation yielded serological evidence suggesting
drug-induced lupus. No effusions recurred following the discontinuation of isoniazid, although other
antituberculosis medications were continued.
Conclusion: The immunological rebound construct is inconsistent with the evolution of this case, which indicates
rather that drug-induced lupus may explain at least some cases of new pleural effusions following the initiation of
isoniazid.
Introduction
Pleural effusions are frequently observed in pulmonary
Mycobacterium tuberculosis infection (TB), occurring in
up to 30% of cases [1]. New onset pleural effusions follow-
ing weeks of antituberculous treatment are far less com-
mon. This clinical scenario, of a delayed emerging effusion
following the initiation of therapy, has been referred to as
a ‘paradoxical’ response [2,3]. Published reports often attri-
bute this to an immunological rebound, in which an exces-
sive antigen load from bacteriolysis is presumed to interact
with a ‘revved-up’ cell-mediated immunity. This model of
a pleural-based response draws on immunological phe-
nomena related to tuberculous lymphadenitis and intra-
cranial tuberculoma [4]. While this has been the
traditional explanation, cases have emerged that suggest a
role for drug-induced lupus mediating this phenomenon
in at least some presentations of delayed effusions follow-
ing the initiation of TB treatment. This report highlights a
case of recurrent pleural effusions stemming from isonia-
zid-induced lupus and discusses the inherent problems
with the presumption that the paradoxical pleural
response to anti-TB therapy explains all effusions arising
during such treatment.
Case presentation
An 84-year-old Asian man was admitted to hospital for
dyspnea and was found to have a large, recurrent right-
sided pleural effusion. This was the third time our patient
presented with an effusion since the initiation of rifampin,
isoniazid, pyrazinamide and ethambutol (RIPE) therapy for
presumed extrapulmonary TB. Nine months prior to this
presentation, our patient underwent a screening colono-
scopy with a biopsy that reportedly yielded a single granu-
lomatous, acid-fast stain-positive, but TB culture-negative
lesion. No anti-TB treatment was initiated at that time.
The purportedly acid-fast stain-positive specimen could
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noscopy with biopsy at six months demonstrated no gran-
ulomas or other evidence of TB. There was no
radiographic evidence of pulmonary TB and interval spu-
tum cultures were negative, as was a serum Quanti-
FERON-TB Gold test. Nevertheless, our patient was
started on RIPE combination therapy.
Four weeks after the initiation of this regimen (two
months prior to the episode described in this report), our
patient complained of dyspnea, cough and weakness. He
was admitted to hospital with the initial right-sided pleural
effusion presentation (Figure 1). Thoracocentesis yielded
exudative, culture- and stain-negative pleural fluid (Table
1). Our patient was given a presumptive diagnosis of a
paradoxical tuberculous effusion and discharged on a
tapering course of systemic glucocorticosteroids while he
continued on RIPE therapy. Two months later, he was re-
admitted with a similar clinical picture. A further liter of
exudative fluid was removed by repeat thoracocentesis
(Figure 1 and Table 1).
Figure 1 Chest X-ray images. (A) Large pleural effusion in his right lung field found on the first admission. (B) Large pleural effusion in his
right lung field on the second admission. (C) Pleural effusion in his right lung field on the current admission, two weeks after the last previous
thoracocentesis. (D) Clear chest X-ray six months after the discontinuation of isoniazid.
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to the admission we report (Figure 1). Our patient
underwent a video-assisted thoracoscopic surgical
biopsy. The pleural fluid again demonstrated a lympho-
cytosis with benign cytology and an adenosine deami-
nase assay yielded a value of 23.8 units per liter (Table
1). Multiple pleural biopsies demonstrated inflammation
without any well-formed granulomata. All cultures of
pleural fluid and biopsies were TB negative. Our
patient’s pleural fluid, which had not been tested serolo-
gically on previous thorocenteses, manifested a low
complement with a total complement activity (CH50) of
10, but was antinuclear antibody (ANA) negative. The
serum ANA titer, however, was elevated to 1:160 with a
speckled pattern, while a serum antihistone assay was
negative. The isoniazid was discontinued, although
rifampin and ethambutol were continued to complete a
nine-month course as recommended by the infectious
disease subspecialty consultants. There have been no
further pleural effusions over two years of follow-up.
Discussion
The application of immunological rebound as an expla-
nation for this case, in which the anti-TB therapy was
empiric and without a convincingly demonstrated infec-
tion, is not consistent with the specific clinical data in
hand. Moreover, the adenosine deaminase value we
observed was below the cut-off point (<35U/L) asso-
ciated with a greater than 90% negative predictive value
for pleural TB, even if the pre-test likelihood of disease
was as high as 70% [5]. A close examination of similar
cases indicates that new effusions can follow the initia-
tion of isoniazid therapy and resolve once that drug is
discontinued [2,3]. Given the well-established associa-
tion of isoniazid with drug-induced lupus (DIL), a
lupus-related explanation of therapy-associated onset of
pleural effusion in TB is quite plausible and avoids the
presumed paradox of immunological rebound. Of note,
serositis is a common feature of DIL, with pleural effu-
sions occurring in as many as 50% of cases, depending
on the inciting drug. DIL serologies were documented
in three previous cases of pleural effusions after anti-TB
therapy involving isoniazid [6,7]. These cases showed a
markedly decreased CH50 in pleural fluid and an ele-
vated ANA in both the serum and the pleural fluid.
Pericardial effusions resulting from isoniazid-induced
lupus have also been reported [8]. The non-specific
ANA serum elevation we observed is consistent with
DIL, as was the pleural effusion resolution following the
removal of isoniazid from the treatment regimen.
Although we did not observe positive serum antihistone
antibodies, these can be negative in as many as a quarter
of DIL cases [9]. While DIL is occasionally associated
with rifampin, the resolution of symptoms in the case
despite continued exposure to this agent argues that it
did not play a role [10].
Conclusion
The case we describe, in conjunction with other cases in
the medical literature, underscores the likely pivotal role
for DIL in at least some new or worsening effusions
during isoniazid treatment. Isoniazid-induced lupus
should be considered in the differential diagnosis of a
treatment emergent effusion and appropriate diagnostic
tests should be pursued before such an effusion is attrib-
uted to a paradoxical pleural response.
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Table 1 Laboratory values for the pleural fluid collected







Color Red Red Yellow
Red blood cells (×10
9/L) 57.25 107 5.575
White blood cells (×10
9/L) 2.075 0.219 0.17
Neutrophils 11% 1% 1%
Lymphocytes 78% 41% 96%
Monocytes 11% 55% 2%
Eosinophils 0% 3% 1%
pH 7.81 - -
Albumin (g/dL) 2.1 - -
Amylase (U/L) -- 6 7
Glucose (mg/dL) 257 212 125
Protein (g/dL) 4.2 3.3 3.3
Lactate dehydrogenase (IU/L) 104 200 224
Triglyceride (mg/dL) -- 2 1
Complement (CH50) -- 1 0
Adenosine deaminase (U/L) - - 23.8




Serum Protein (g/dL) 6.2 - -
Note: Dash (-) indicates that the test was not performed on the sample in
question.
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